Related Experiment Video
Updated: Jun 6, 2026
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
1New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico 87106, USA. lewiecki@aol.com
Importance Of The Field:
Osteoporosis is a common skeletal disease characterized by loss of bone strength that leads to increased risk of fractures. Fractures of the hip and spine are associated with disability, increased risk of death and high healthcare costs. Recent improvement in the understanding of the molecular regulators of bone metabolism has led to the investigation and development of new therapeutic agents with novel mechanisms of action that may offer advantages over currently available treatments for osteoporosis.
Areas Covered In This Review:
Sclerostin is a small protein secreted by osteocytes that downregulates osteoblast-mediated bone formation. This is a review of the rationale, mechanism of action, preclinical and clinical development of AMG 785 (CDP7851), an investigational humanized mAb that inhibits the activity of sclerostin, resulting in increased bone formation.
What The Reader Will Gain:
The reader will gain an insight into the potential use of sclerostin mAb therapy for the treatment of osteoporosis.
Take Home Message:
Preclinical studies and an early report of a clinical study suggest that inhibition of sclerostin with AMG 785 may provide skeletal benefit for patients with osteoporosis.
Insights
Sclerostin monoclonal antibody therapy, like AMG 785, shows promise for treating osteoporosis by increasing bone formation. This approach may offer skeletal benefits for patients with this common bone disease.
Area of Science:
- Osteoporosis research
- Bone metabolism and therapeutics
- Sclerostin inhibition
Background:
- Osteoporosis is a prevalent skeletal disease marked by reduced bone strength, increasing fracture risk.
- Hip and spine fractures lead to significant disability, mortality, and healthcare expenses.
- Advances in understanding bone metabolism drive the development of novel osteoporosis treatments.
Purpose of the Study:
- To review the rationale, mechanism, and development of AMG 785 (CDP7851).
- To explore the potential of sclerostin inhibition for osteoporosis treatment.
Main Methods:
- Review of preclinical and clinical data for AMG 785.
- Focus on AMG 785 as a humanized monoclonal antibody targeting sclerostin.
Main Results:
- Sclerostin downregulates osteoblast-mediated bone formation.
- AMG 785 inhibits sclerostin activity, promoting bone formation.
Conclusions:
- Preclinical studies indicate skeletal benefits of sclerostin inhibition.
- Early clinical data suggest AMG 785 may benefit osteoporosis patients.
